The technology originated and found out by Maurizio Zanetti.

TeloB-VAX prostate cancers vaccine has been proven to induce a powerful cellular immune response against the 1st truly common cancer marker, the telomerase reverse transcriptase . Telomerase was the subject of the Nobel Prize for Medication in ’09 2009. Related StoriesStudy displays uncommon HER2 missense mutations usually do not spread breast cancer on the ownNew RNA check of blood platelets can be used to detect location of cancerSausages With Antioxidants From Berries To Prevent CancerA Phase 1 study finished at UCSD in castrate resistant prostate cancer sufferers demonstrated this vaccine to become safe, immunogenic and non-toxic. Two shots of TeloB-VAX, spaced a month apart, were proven to induce a particular CD8 T cell response.I am very proud that so many of our locations have adopted this program and are producing a difference within their communities. For details about each winning strategy, start to see the cover tale of Assisted Living Executive’s May/June 2010 issue. The ALFA 2010 Greatest of the greatest Award winners will also be regarded at the ALFA 2010 Meeting & Expo, May 25-27, in Phoenix. Additionally, Emeritus associates will be sharing their expertise at the ALFA Meeting. Jayne Sallerson, Executive Vice President of Product sales and Advertising, will be taking part in a forum titled, Shaping the Future, a conversation on what 2013 can look like for the assisted living industry. Chris Hyatt, Executive Vice President and Chief Working Officer for Emeritus, will be speaking as part of a panel titled, Emerging From the Recession, where he shall share lessons learned from the economic depression.

ATHENA develops surrogate organ program for toxicity testing Creating surrogate human being organs, coupled with insights from sensitive mass spectrometry technologies highly, a new project is on the brink of revolutionizing the true way we screen new drugs and toxic brokers.